<DOC>
	<DOCNO>NCT02802267</DOCNO>
	<brief_summary>Evaluate effect addition inecalcitol decitabine treatment overall survival previously untreated AML patient age 65 year randomly assign receive decitabine without inecalcitol .</brief_summary>
	<brief_title>Efficacy Study Inecalcitol With Decitabine Acute Myeloid Leukemia Patients Unfit Standard Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>• Patients age 65 &lt; 75 year least one non severe comorbidity ie disease syndrome mild moderate clinical diagnostic observation lab abnormality could increase risk toxicity and/or early death intensive chemotherapy opinion investigator contraindicate nonintensive chemotherapy . ≥ 75 year without comorbidity time inform consent signature ; • Newly diagnose , histologically confirm , untreated de novo secondary AML accord WHO classification ; Prior current treatment chemotherapy myeloid disorder ( exclude hydroxyurea ) radiotherapy extramedullary involvement within 2 week randomization ; Prior treatment decitabine , azacitidine , cytarabine ; Prior malignancies 5 year exception basal cell , squamous cell carcinoma skin , carcinoma `` situ `` cervix breast ; Chronic myelogenous acute promyelocytic leukaemia ; Karyotype anomaly CBF ; Known CNS involvement ; A plan bone marrow stem cell transplant within 12 week randomization ; WBC ≥ 30.000/mm3 ; Impaired renal function Creatinine clearance &lt; 30 mL/min/1.73m² accord MDRD formula ; Serum bilirubin ≥ 2.5 x ULN and/or AST and/or ALT ≥ 2.5 x ULN ( upper limit normal value ) ; Hypercalcemia screen assessment ( correct albuminemia ) ; History diseases know associated calcium disorder : ongoing hyperparathyroidism , sarcoidosis… . ; Presence history symptomatic kidney stone last 5 year ; Hypersensitivity excipients decitabine ( Potassium dihydrogen phosphate ( E340 ) ; Sodium hydroxide ( E524 ) ; Hydrochloric acid ( pH adjustment ) excipient inecalcitol tablet ( lactose ) ; Current use drug know influence serum calcium ( thiazide diuretic , teriparatide , calcitonin multivitamin supplement contain &gt; 400 IU vitamin D calcium ) ; Current use digitalis ; Current use drug could influence bioavailability inecalcitol ( magnesiumcontaining antacid , bileresin binder ) ; Use experimental drug therapy vitamin D supplementation within 4 week randomization ; Known HIV ; Patients eligible intensive induction therapy curative intent ; Refractory congestive heart failure ; Active infection resistant antiinfective therapy ; Documented pulmonary disease DLCO ≤ 65 % FEV1≤ 65 % , dyspnea rest require oxygen , pleural neoplasm uncontrolled lung neoplasm ; Liver cirrhosis Child B C acute viral hepatitis ; Current mental illness require psychiatric hospitalization , institutionalization intensive outpatient management , current cognitive status produce dependence ( confirmed specialist ) control caregiver ; Uncontrolled neoplasia ;</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>